NCT02089048View on ClinicalTrials.gov

Auranofin PK Following Oral Dose Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 2, 2014

Primary Completion Date

September 9, 2014

Study Completion Date

May 13, 2015

Conditions
Amoebiasis
Interventions
DRUG

Auranofin

Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days

Trial Locations (1)

66211-1553

Quintiles Phase I Services - Overland Park, Overland Park

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02089048 - Auranofin PK Following Oral Dose Administration | Biotech Hunter | Biotech Hunter